HIV Drugs Market Report 2025 (Global Edition)

Global HIV Drugs Market Report 2025 Market Size Split by Product Type (Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibito...

HIV Drugs Market Report Description

We have various report editions of HIV Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.

The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.

Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.

Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.

Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.

HIV Drugs Market Insights Video

Competitive Landscape of the HIV drugs Market

The landscape of the HIV drugs market is highly competitive with a range of players focusing on R&D, innovation in antiretroviral therapies, and strategic collaborations. The market is also seeing the emergence of generic drug manufacturers, intensifying competition. Continuous advancements in treatment options and patent expirations shape the competitive landscape.

In June 2023 - Lupin Limited announced the introduction of Darunavir Tablets, 600 mg and 800 mg in the U.S. market. This drug is a generic version of Prezista Tablets of Janssen Products, LP. (Source: https://www.lupin.com/lupin-launches-darunavir-tablets-in-the-united-states/) In February 2022 - ViiV Healthcare received the U.S. FDA approval Cabenuva (cabotegravir, rilpivirine) for the treatment of individuals having HIV infection. (Source: https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2022/january/viiv-healthcare-announces-fda-approval-of-cabenuva-for-use-every-two-months/#:~:text=Today's%20approval%20is%20a%20remarkable,as%20six%20times%20a%20year.%E2%80%9D)

Top Companies Market Share in HIV Drugs Industry: (In no particular order of Rank)

• ViiV Healthcare (U.S.)
• Gilead Sciences
• Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Merck & Co.
• Inc. (Germany)
• Bristol-Myers Squibb Company (U.S.)
• Johnson & Johnson Services
• Inc. (Janssen Pharmaceuticals
• Inc.) (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• AbbVie Inc. (U.S.)
• F. Hoffmann-La Roche AG (Genentech
• Inc.) (U.S.)
• Mylan N.V. (U.S.)
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the HIV drugs Market

Which Region Dominates the HIV drugs Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024. It accounted for around 40% of the global revenue due to the advanced healthcare infrastructure, significant government initiatives, substantial investments in research and development, the presence of key pharmaceutical companies, widespread access to antiretroviral therapy, strong healthcare support systems, adoption of innovative treatments, such as single-tablet regimens and long-acting injectables, alongside increasing awareness and testing initiatives.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the HIV drugs market due to the increased awareness, government initiatives, expanding healthcare infrastructure, rising HIV prevalence, partnerships between governments, NGOs, and pharmaceutical companies and advancements in drug formulations and generic drug availability, making treatment more affordable.

The current report Scope analyzes HIV Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America HIV Drugs Market

According to Cognitive Market Research, the global HIV drugs market size was estimated at USD 35425.2 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 14170.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.0% from 2024 to 2031.

• According to Cognitive Market Research, the U.S. had a major share in the HIV drugs market with a market size of USD 11180.19 million in 2024 and is projected to grow at a CAGR of 4.8% during the forecast period. The nation's rising demand for efficient treatment options.
• The Canada HIV drugs market had a market share of USD 1700.41 million in 2024 and is projected to grow at a CAGR of 5.8% during the forecast period. Canada's advancements in antiretroviral therapy drives growth.
• The Mexico HIV drugs market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD 1289.48 million in 2024.

Europe HIV Drugs Market

According to Cognitive Market Research, the global HIV drugs market size was estimated at USD 35425.2 Million, out of which Europe held the market of more than 30% of the global revenue with a market size of USD 10627.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031.

• The United Kingdom HIV drugs market had a market share of USD 1785.43 million in 2024 and is projected to grow at a CAGR of 6.1% during the forecast period. In the U.K., HIV drugs sales witness an upswing due to the rise in government funding for HIV treatment.
• The France HIV drugs market is projected to witness growth at a CAGR of 4.5% during the forecast period, with a market size of USD 977.74 million in 2024.
• According to Cognitive Market Research, the German HIV drugs market size was valued at USD 2104.26 million in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period. In Germany, HIV drugs surged due to the advancements in drug formulations.
• The Italy HIV drugs market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 913.97 million in 2024.
• The Russian HIV drugs market is projected to witness growth at a CAGR of 4.3% during the forecast period, with a market size of USD 1647.27 million in 2024.
• The Spain HIV drugs market is projected to witness growth at a CAGR of 4.4% during the forecast period with a market size of USD 871.46 million in 2024
• The Luxembourg HIV drugs market is projected to witness growth at a CAGR of 5.4% during the forecast period, with a market size of USD 329.45 million in 2024.
• The Portugal HIV drugs market is projected to witness growth at a CAGR of 5.1% during the forecast period, with a market size of USD 223.18 million in 2024.
• The Greece HIV drugs market is projected to witness growth at a CAGR of 5.6% during the forecast period, with a market size of USD 127.53 million in 2024.
• Rest of Europe's HIV drugs market is projected to witness growth at a CAGR of 4.0% during the forecast period, with a market size of USD 1647.27 million in 2024.

Asia Pacific HIV Drugs Market

According to Cognitive Market Research, the global HIV drugs market size was estimated at USD 35425.2 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 8147.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031.

• According to Cognitive Market Research, the China HIV drugs market size was valued at USD 3666.51 million in 2024 and is projected to grow at a CAGR of 8.3% during the forecast period. HIV drugs surged in China due to the growing government initiatives and support.
• The Japan HIV drugs market is projected to witness growth at a CAGR of 7.3% during the forecast period, with a market size of USD 1124.40 million in 2024.
• The India HIV drugs market had a market share of USD 977.74 million in 2024 and is projected to grow at a CAGR of 10.6% during the forecast period. India's improved access to healthcare facilities augments the demand.
• The South Korean HIV drugs market is projected to witness growth at a CAGR of 7.9% during the forecast period, with a market size of USD 814.78 million in 2024.
• The Australian HIV drugs market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 423.69 million in 2024.
• The South East Asia HIV drugs market is projected to witness growth at a CAGR of 9.8% during the forecast period, with a market size of USD 562.20 million in 2024.
• The Rest of Asia Pacific HIV drugs market is projected to witness growth at a CAGR of 8.6% during the forecast period, with a market size of USD 578.49 million in 2024.

South America HIV Drugs Market

According to Cognitive Market Research, the global HIV drugs market size was estimated at USD 35425.2 Million, out of which the Latin America market has more than 5% of the global revenue with a market size of USD 1771.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031. .

• According to Cognitive Market Research, the Brazil HIV drugs market size was valued at USD 758.10 million in 2024 and is projected to grow at a CAGR of 6.8% during the forecast period. HIV drugs flourished in Brazil due to the availability of generic options.
• Argentina's HIV drugs market had a market share of USD 297.57 million in 2024 and is projected to grow at a CAGR of 7.1% during the forecast period. Argentina's increased government support augments the demand.
• Colombia's HIV drugs market is projected to witness growth at a CAGR of 6.0% during the forecast period, with a market size of USD 157.64 million in 2024.
• Peru's HIV drugs market is projected to witness growth at a CAGR of 6.4% during the forecast period, with a market size of USD 145.24 million in 2024.
• Chile's HIV drugs market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 127.53 million in 2024.
• The Rest of Latin America's HIV drugs market is projected to witness growth at a CAGR of 5.3% during the forecast period, with a market size of USD 285.17 million in 2024.

Middle East HIV Drugs Market

According to Cognitive Market Research, the global HIV drugs market size was estimated at USD 35425.2 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 708.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031..

• The GCC Countries' HIV drugs market is projected to witness growth at a CAGR of 7.3% during the forecast period, with a market size of USD 303.24 million in 2024. HIV drugs sales flourish due to the growing demand generic medications.
• The Egypt HIV drugs market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD 74.39 million in 2024.
• The South African HIV drugs market is projected to witness growth at a CAGR of 7.5% during the forecast period, with a market size of USD 111.94 million in 2024. HIV drugs sales flourish in South Africa due to expansion of healthcare infrastructure.
• The Turkey HIV drugs market is projected to witness growth at a CAGR of 6.0% during the forecast period, with a market size of USD 60.93 million in 2024.
• The Nigeria HIV drugs market is projected to witness growth at a CAGR of 5.6% during the forecast period, with a market size of USD 74.39 million in 2024.
• The Rest of the MEA HIV drugs market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD 83.60 million in 2024.

HIV Drugs Market Analysis

HIV drugs Market Product Type Segment Analysis

According to Cognitive Market Research, Multi-Class Combination Drugs stands out as the dominant category over the projected period due to their ability to simplify treatment regimens by combining multiple antiretroviral drugs into a single pill. This approach enhances patient adherence and reduces the likelihood of drug resistance.

Nucleoside Reverse Transcriptase Inhibitors (NRTIs) emerges as the fastest-growing category in the HIV drugs market. They inhibit the action of reverse transcriptase, an enzyme crucial for viral replication. Despite the rise of combination therapies, NRTIs continue to play a critical role in both first-line and salvage therapy regimens, particularly in resource-limited settings.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of HIV Drugs Industry. Request a Free Sample PDF!

HIV drugs Market Distribution Channel Segment Analysis

According to Cognitive Market Research, the dominant category is hospital pharmacies. These play a significant role by providing specialized care and tailored drug regimens for patients requiring complex HIV treatments. These pharmacies often handle high volumes of prescriptions, including antiretroviral therapy (ART), and have the advantage of direct integration with patient care teams.

The fastest-growing category in the HIV drugs market is drugs stores and retail pharmacies. They cater to a broader customer base, offering convenience and accessibility. They stock a range of HIV medications, including both branded and generic options, and are essential for routine refills and ongoing management of the condition.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion